165 related articles for article (PubMed ID: 18073170)
1. Respiratory syncytial virus infection and recurrent wheezing: what next?
Puddu M; Fanos V
J Chemother; 2007 Oct; 19 Suppl 2():8-11. PubMed ID: 18073170
[TBL] [Abstract][Full Text] [Related]
2. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
[TBL] [Abstract][Full Text] [Related]
3. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children.
Simões EA; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick L; Groothuis JR;
J Allergy Clin Immunol; 2010 Aug; 126(2):256-62. PubMed ID: 20624638
[TBL] [Abstract][Full Text] [Related]
4. Palivizumab Prophylaxis in Preterm Infants and Subsequent Recurrent Wheezing. Six-Year Follow-up Study.
Mochizuki H; Kusuda S; Okada K; Yoshihara S; Furuya H; Simões EAF;
Am J Respir Crit Care Med; 2017 Jul; 196(1):29-38. PubMed ID: 28152315
[TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.
Blanken MO; Rovers MM; Molenaar JM; Winkler-Seinstra PL; Meijer A; Kimpen JL; Bont L;
N Engl J Med; 2013 May; 368(19):1791-9. PubMed ID: 23656644
[TBL] [Abstract][Full Text] [Related]
6. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants.
Yoshihara S; Kusuda S; Mochizuki H; Okada K; Nishima S; Simões EA;
Pediatrics; 2013 Nov; 132(5):811-8. PubMed ID: 24127479
[TBL] [Abstract][Full Text] [Related]
7. Ethical considerations and rationale of the MAKI trial: a multicenter double-blind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks.
Blanken M; Rovers M; Sanders E; Bont L
Contemp Clin Trials; 2012 Nov; 33(6):1287-92. PubMed ID: 22820319
[TBL] [Abstract][Full Text] [Related]
8. Palivizumab prophylaxis in preterm infants and subsequent wheezing/asthma: 10-year follow-up study.
Kato M; Mochizuki H; Kama Y; Kusuda S; Okada K; Yoshihara S; Furuya H; Simões EAF;
Pediatr Pulmonol; 2024 Mar; 59(3):743-749. PubMed ID: 38116923
[TBL] [Abstract][Full Text] [Related]
9. Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season.
Fanos V; Scarcella A; Puddu M; Gallini F; Tuminelli F; Bragetti P; Gallina MR; Quartulli L; Benincori N; Citro G; Via LD; Barera G; DI Luzio Paparatti U; Merolla R; Romano GV; Guida G; Silvestri M; Rossi GA
J Chemother; 2009 Jun; 21(3):302-10. PubMed ID: 19567351
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
Sanchez-Luna M; Burgos-Pol R; Oyagüez I; Figueras-Aloy J; Sánchez-Solís M; Martinón-Torres F; Carbonell-Estrany X
BMC Infect Dis; 2017 Oct; 17(1):687. PubMed ID: 29041909
[TBL] [Abstract][Full Text] [Related]
11. Airflow limitation during respiratory syncytial virus lower respiratory tract infection predicts recurrent wheezing.
Bont L; Van Aalderen WM; Versteegh J; Brus F; Draaisma JT; Pekelharing-Berghuis M; Van Diemen-Steenvoorde RA; Kimpen JL
Pediatr Infect Dis J; 2001 Mar; 20(3):277-82. PubMed ID: 11303830
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Burden and Respiratory Effects of Respiratory Syncytial Virus Hospitalization in Preterm Infants-The SPRING Study.
Carbonell-Estrany X; Pérez-Yarza EG; García LS; Guzmán Cabañas JM; Bòria EV; Atienza BB;
PLoS One; 2015; 10(5):e0125422. PubMed ID: 25955487
[TBL] [Abstract][Full Text] [Related]
13. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
14. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
[TBL] [Abstract][Full Text] [Related]
15. The association between respiratory syncytial virus infection and reactive airway disease.
Piedimonte G
Respir Med; 2002 Apr; 96 Suppl B():S25-9. PubMed ID: 11996401
[TBL] [Abstract][Full Text] [Related]
16. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain.
Figueras-Aloy J; Carbonell-Estrany X; Quero J;
Pediatr Infect Dis J; 2004 Sep; 23(9):815-20. PubMed ID: 15361718
[TBL] [Abstract][Full Text] [Related]
17. Persistent recurring wheezing in the fifth year of life after laboratory-confirmed, medically attended respiratory syncytial virus infection in infancy.
Escobar GJ; Masaquel AS; Li SX; Walsh EM; Kipnis P
BMC Pediatr; 2013 Jun; 13():97. PubMed ID: 23782528
[TBL] [Abstract][Full Text] [Related]
18. RSV, recurrent wheezing, and ribavirin.
McBride JT; McConnochie KM
Pediatr Pulmonol; 1998 Mar; 25(3):145-6. PubMed ID: 9556004
[No Abstract] [Full Text] [Related]
19. Respiratory syncytial virus infection: clinical features, management, and prophylaxis.
Greenough A
Curr Opin Pulm Med; 2002 May; 8(3):214-7. PubMed ID: 11981311
[TBL] [Abstract][Full Text] [Related]
20. Comparison of clinical features of acute lower respiratory tract infections in infants with RSV/HRV infection, and incidences of subsequent wheezing or asthma in childhood.
Ding Q; Xu L; Zhu Y; Xu B; Chen X; Duan Y; Xie Z; Shen K
BMC Infect Dis; 2020 May; 20(1):387. PubMed ID: 32473625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
